US4404137A - Pyrazolo [3,4-b][1,5]benzodiazepine compounds - Google Patents

Pyrazolo [3,4-b][1,5]benzodiazepine compounds Download PDF

Info

Publication number
US4404137A
US4404137A US06/193,200 US19320080A US4404137A US 4404137 A US4404137 A US 4404137A US 19320080 A US19320080 A US 19320080A US 4404137 A US4404137 A US 4404137A
Authority
US
United States
Prior art keywords
methyl
alkyl
formula
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/193,200
Other languages
English (en)
Inventor
Jiban K. Chakrabarti
Terrence M. Hotten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Assigned to LILLY INDUSTRIES LIMITED reassignment LILLY INDUSTRIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: CHAKRABARII, JIBAN K., Hotten, Terrence M.
Application granted granted Critical
Publication of US4404137A publication Critical patent/US4404137A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to novel compounds, process for preparing them and their use as pharmaceuticals.
  • a particular group of compounds of formula (I) is one in which R 1 , R 2 and R 3 independently represent hydrogen, C 1-4 alkyl, C 2-4 alkenyl, halogen, C 1-4 haloalkyl, nitro, C 1-4 alkoxy, C 1-4 haloalkoxy, C 1-4 alkylthio, C 1-4 haloalkylsulphonyl or phenylsulphonyl, R 4 is hydrogen, R 6 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl or benzyl, R 7 is hydrogen or C 1-4 alkyl, R 9 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl or benzyl, and R 10 is hydrogen or C 1-4 alkyl.
  • a preferred group of compounds is one of the following formula (II) ##STR6## or an acid addition salt thereof; in which R 1 , R 2 and R 3 independently represent hydrogen, C 1-4 alkyl, C 2-4 alkenyl, halogen, C 1-4 haloalkyl, nitro, C 1-4 alkoxy, C 1-4 alkylthio or phenylsulphonyl, R 6 is hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl or benzyl, R 7 is hydrogen or C 1-10 alkyl and R 9 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl or benzyl.
  • a preferred group of compounds of formula (II) is one in which R 1 , R 2 and R 3 independently represent hydrogen, halogen or C 1-4 haloalkyl, R 6 is C 1-6 alkyl, C 3-7 cycloalkyl or C 3-7 cycloalkyl C 1-4 alkyl, R 7 is hydrogen and R 9 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl C 1-4 alkyl or benzyl, the compounds in which R 9 is hydrogen being useful as intermediates in the preparation of preferred compounds.
  • R 2 and R 3 both represent halogen, especially fluorine or chlorine and R 1 is hydrogen.
  • R 3 is halogen, especially fluorine, and R 1 and R 2 are hydrogen.
  • R 7 is hydrogen
  • C 1-10 alkyl means a straight or branched chain alkyl group containing 1 to 10 carbon atoms and is especially, for example, methyl, ethyl, isopropyl, propyl, butyl, sec.butyl, isobutyl, tert, butyl, pentyl and hexyl.
  • a preferred alkyl group is "C 1-4 alkyl”.
  • C 1-4 haloalkyl means any such alkyl group substituted by one or more, preferably three halogen atoms, and is especially trifluoromethyl.
  • C 1-4 alkoxy and C 1-4 alkylthio mean any C 1-4 alkyl group attached through an oxygen or sulphur atom to a ring atom and "C 1-4 haloalkoxy” means a C 1-4 alkoxy group substituted by one or more, preferably three halogen atoms and is especially trifluoromethoxy.
  • C 1-4 carbalkoxy means a C 1-4 alkoxy group attached via a carbonyl group to a ring atom.
  • C 1-4 Alkanoyl includes the formyl group and groups of the formula R 11 CO where R 11 is C 1-4 alkyl.
  • C 2-4 alkenyl refers to groups such as vinyl, allyl and butenyl.
  • amino indicates a group of formula --NH 2 and also substituted amino groups such as mono-C 1-4 alkylamino and di-C 1-4 alkylamino groups.
  • C 2-4 acylamino means an amino group substituted by a C 2-4 acyl group especially acetyl.
  • C 3-7 Cycloalkyl means a saturated ring having 3 to 7 carbon atoms in the ring such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, which can, in the group “C 3-7 cycloalkyl C 1-4 alkyl", be attached to the ring via an alkyl chain having 1 to 4 carbon atoms.
  • optionally substituted phenyl means, a phenyl group which is unsubstituted or substituted by one or more groups, for example, halogen, C 1-4 haloalkyl, C 1-4 alkyl C 1-4 alkoxy or nitro. Specific examples of such substituents include chlorine, trifluoromethyl, methyl and methoxy.
  • the acid addition salts are preferably the pharmaceutically acceptable, non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric or lactic acid, or organic sulphonic acids for example methane suphonic, ethane sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic or naphthalene-2-sulphonic acid.
  • suitable acids such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids
  • organic acids such as organic carboxylic acids, for example, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric or lactic acid, or organic sulph
  • acid addition salts such as, for example, those with picric or oxalic acid, since they may serve as intermediates in the purification of the compounds or in the preparation of other, for example, pharmaceutically acceptable, acid addition salts, or are useful for identification, characterization or purification of the bases.
  • the radical Q can be hydroxyl, thiol, an alkoxy or alkylthio group containing 1 to 4 carbon atoms, for example a methoxy or methylthio group, a halogen atom, especially a chlorine atom, an amino group or a mono- or dialkyl-substituted amino group, each alkyl substituent containing 1 to 4 carbon atoms.
  • Q is hydroxyl, thiol, C 1-4 alkoxy, C 1-4 alkylthio, halogen or amino and it is especially preferred that Q is hydroxyl, thiol or amino (NH 2 ).
  • reaction (a) can be accomplished in the presence of titanium tetrachloride which has the ability to react with the amine of formula R 5 H to form a metal amine complex.
  • titanium tetrachloride which has the ability to react with the amine of formula R 5 H to form a metal amine complex.
  • Other metal chlorides such as those of zirconium, hafnium or vanadium may also be employed.
  • the reaction is preferably carried out in the presence of an acid binding agent such as a tertiary amine, for example, triethylamine.
  • the reaction can be carried out using excess of the amine of formula R 5 H to act as an acid-binding agent.
  • a suitable organic solvent such as toluene or chlorobenzene can be used as reaction medium, although it has been found that the use of anisole is particularly desirable, at least as a co-solvent, in view of its ability to form a soluble complex with TiCl 4 .
  • elevated temperatures for example up to 200° C.
  • a preferred temperature range for carrying out the reaction is from 100° C. to 150° C.
  • amidines of formula (III) can be in a salt form for example as the hydrochloride, and they can be similarly reacted with amines of formula R 5 H, optionally diluted with a solvent such as anisole, dimethylformamide or dimethylsulphoxide, and optionally using a catalyst such as TiCl 4 at a temperature range of 100° to 150°.
  • a solvent such as anisole, dimethylformamide or dimethylsulphoxide
  • a catalyst such as TiCl 4 at a temperature range of 100° to 150°.
  • the amidine can be converted into the corresponding amide of formula (III) (Q is OH) by alkaline hydrolysis.
  • Thioamides of formula (III) (Q is SH), iminothioethers, iminoethers or iminohalides, or other derivatives containing active Q radicals as specified above, tend to be more reactive towards the amine R 5 H and can usually be reacted without the necessity for the presence of TiCl 4 , but otherwise employing the same conditions of temperature and solvent.
  • reaction (b) compounds of formula (IV) are ring-closed by employing, for example, the same conditions in terms of catalyst and solvent as those described above for reaction (a) and preferably at a temperature of 150° C. to 200° C.
  • the compounds of formula (IV) are conveniently prepared in situ without isolation.
  • the compound prepared by reaction (a) or (b) is one in which R 6 or R 9 is hydrogen, it may be further reacted to provide other compounds of the invention.
  • R 6 is hydrogen
  • the compound can be reacted with R 6 X by conventional alkylation or acylation type methods, X being a leaving group.
  • the compound is dissolved in a suitable inert polar solvent such as ethanol and the reagent of formula R 6 X added, the reaction mixture then being heated under reflux in the presence of a base.
  • the group X can be a suitable reactive atom such a chlorine, bromine or iodine, or a reactive group such as tosyl or mesyl.
  • R 9 is hydrogen
  • the compound can be reacted with a reagent of formula R 9 X in an inert solvent and in the presence of a base.
  • Suitable oxidising agents include for example m-chloroperbenzoic acid and the reaction is preferably carried out in an inert solvent such as for example dichloromethane at a temperature of from -10° C. to +10° C.
  • the compounds of formula (I) produced by the above processes may be isolated per se or may be converted to their corresponding acid addition salts using conventional methods.
  • the amides of formula (III) (Q is OH) can be prepared by a process which involves the ring-closure of an amino-ester of formula (V) ##STR11## where R 12 is a C 1-4 alkyl group, employing for example sodium methylsulphinyl methanide in a suitable solvent such a dimethyl sulphoxide.
  • amides of formula (III) (Q is OH) can be prepared by ring-closure of an amino-acid of formula (VI) ##STR12## employing for example dicyclohexylcarbodiimide (DCC) in a suitable solvent such as tetrahydrofuran.
  • DCC dicyclohexylcarbodiimide
  • tetrahydrofuran a suitable solvent
  • amino-acids can be obtained from the esters of formula (V) by basic hydrolysis using for example sodium hydroxide in ethanol.
  • the esters of formula (V) can be prepared by condensation of a pyrazole compound of formula ##STR13## with an ortho-halonitrobenzene of formula ##STR14## where Z is halogen, preferably fluorine, chlorine or bromine, in the presence of a base for example, sodium hydride in a solvent such as tetrahydrofuran or dimethylformamide, n-butyl lithium in tetrahydrofuran, potassium carbonate in dimethylsulphoxide or with a tetralkylammonium salt in a two-phase system, to form a nitro ester of formula ##STR15## which can be reduced to the amino ester of formula (V) catalytically, employing for instance hydrogen and palladium or chemically, employing for example, stannous chloride and hydrogen chloride in aqueous ethanol, or ammonium polysulphide.
  • a base for example, sodium hydride in a solvent such as tetrahydrofuran or dimethylform
  • Pyrazole starting materials used in the processes described above are either known compounds, see for example J. Am. Chem. Soc. (1956) 78 784; Helv. Chim. Acta (1958) 41 1052; Helv. Chim. Acta (1959) 42 349 and 763; German Pat. No. 1,106,330 and British Pat. No. 884,851; or can be prepared by conventional techniques from known compounds.
  • the ortho-halonitrobenzene intermediates are either commercially available or can be simply prepared from commercially available substances.
  • Thioamides of formula (III) (Q is SH) can be prepared by treating a solution of the corresponding amide in an anhydrous basic solvent such as for example pyridine with phosphorus pentasulphide.
  • the amides can be converted to iminothioethers, iminoethers or iminohalides, or other derivatives containing active Q radicals, by treatment with conventional reagents such as for example in the case of an iminochloride, phosphorus pentachloride.
  • the compounds of formula (IV) are novel and they are included as a further aspect of this invention. They can be prepared in situ without isolation by reacting a compound of formula (V) with an amine of formula R 5 H such as by heating to a temperature between 30° C. and 120° C., for example 100° C., in a suitable solvent such as for example anisole and employing TiCl 4 as catalyst, or by conventional methods from compounds of formula (V) or (VI).
  • electrophilic substitution on the aromatic nucleus can be carried out on compounds of formulae (I), (III) or (IV) in conventional manner to produce other derivatives.
  • an amide of formula (III) can be acetylated using acetyl chloride and stannic chloride or halogenated employing for example N-chlorosuccinimide, to give the corresponding acetyl or chloro derivatives.
  • Products of formula (I) in which R 1 , R 2 , R 3 or R 4 is amino can be acylated or alkylated in conventional manner to form the corresponding acylamino or alkylamino derivatives.
  • Preferred compounds have also been tested following chronic administration when a behavioural supersensitivity is produced to locally injected dopamine in a manner similar to that described in Psychopharmacologia (1975) 45 151-155.
  • the activity profile observed in this test along with the lack of response in tests such as the production of catalepsy indicate that these compounds possess useful central nervous system activity and do not produce certain undesirable side effects.
  • conventional central nervous system drugs can have undesirable characteristics and the potential absence of these side effects in compounds according to the invention represents a significant advance.
  • compounds of the invention possess unexpected anxiolytic activity as demonstrated by their profile in the test described in Neuropharmacology (1979) 18 689-695.
  • the compounds of formula (I) and acid addition salts thereof are thus, potent centrally acting compounds with neuroleptic, sedative, relaxant, anxiolytic or anti-emetic properties. These properties, coupled with their low toxicity render them useful in the treatment of mild anxiety states and certain kinds of psychotic conditions such a schizophrenia and acute mania.
  • the compounds of this invention are effective over a wide dosage range, the actual dose administered being dependent on such factors as the particular compound being used, the condition being treated and the type and size of mammal being treated.
  • the dosage required will normally fall within the range of 0.5 to 50 mg/kg per day, for example in the treatment of adult humans, dosages of from 5 to 500 mg per day may be used.
  • compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • the invention includes a pharmaceutical composition comprising as active ingredient a compound of formula I or an acid addition salt thereof, associated with a pharmaceutically acceptable carrier.
  • the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier When the carrier serves as a diluent, it may be a solid, semi-solid or liquid matrial which acts as a vehicle, excipient or medium for the active ingredient.
  • suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydroxybenzoate, talc, magnesium stearate or mineral oil.
  • the compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • compositions may be formulated as tablets, capsules or suspensions for oral use and injection solutions for parenteral use or as suppositories.
  • the compositions are formulated in a dosage unit form, each dosage containing from 1 to 200 mg, more usually 5 to 100 mg, of the active ingredient.
  • a solution of sodium methyl sulphinyl methanide was generated by stirring sodium hydride (50% oil dispersion, 1.5 g) in dry dimethylsulphoxide (15 ml) at 65° C. until gas evolution ceased.
  • a solution of ethyl 3-(2-amino-4-fluoroanilino)-1-methylpyrazole-4-carboxylate (2.7 g) dissolved in dry dimethyl sulphoxide (5 ml) was added dropwise and the mixture stirred at 65° C. for 20 minutes. The mixture was poured on to excess ice-water, filtered and dried to give the title compound which was crystallised from chloroform-hexane m.p. 264° C.
  • Ethyl 3-(2-amino-4-fluoroanilino)-1-ethylpyrazole-4-carboxylate (2.64 g) was dissolved in a mixture of N-methyl piperazine (12.5 ml.) and anisole (50 ml). Titanium tetrachloride (3 ml) in anisole (12 ml) was added, dropwise, and the stirred solution was heated at reflux under an atmosphere of dry nitrogen for 24 hours. The mixture was cooled to 60° C. and a mixture of isopropanol (10 ml) and 0.88 ammonia solution (10 ml) cautiously added.
  • the citrate salt was prepared by adding a solution of citric acid in ethanol to a solution of the title compound in a 1:1 mixture of ethanol and ethyl acetate m.p. 138° C. (softens)
  • the active ingredient, starch and cellulose were passed through a No. 44 mesh B.S. sieve and mixed thoroughly.
  • the solution of polyvinylpyrrolidone was mixed with the resultant powders which were then passed through a No. 12 mesh B.S. sieve.
  • the granules so produced were dried at 50°-60° C. and passed through a No. 16 mesh B.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh B.S. sieve, were then added to the granules which, after mixing, were compressed on a tablet machine to yield tablets each weighting 100 mg.
  • Capsules each containing 20 mg of medicament were made as follows
  • the active ingredient, cellulose, starch and magnesium stearate were passed though a No. 44 mesh B.S. sieve and filled into hard gelatin capsules in 200 mg quantities.
  • the active ingredient was passed through a No. 60 mesh B.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture was then poured into a suppository mould of nominal 2 g capacity and allowed to cool.
  • the medicament was passed through a No. 44 mesh B.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavour and colour were diluted with some of the water and added, with stirring. Sufficient water was then added to produce the required volume.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
US06/193,200 1979-10-16 1980-10-02 Pyrazolo [3,4-b][1,5]benzodiazepine compounds Expired - Lifetime US4404137A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7935846 1979-10-16
GB7935846 1979-10-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US06/426,580 Division US4486591A (en) 1979-10-16 1982-09-29 4-Substituted-1-(3-[2-aminoanilino]-1-pyrazole-4-carbonyl)piperazine

Publications (1)

Publication Number Publication Date
US4404137A true US4404137A (en) 1983-09-13

Family

ID=10508540

Family Applications (3)

Application Number Title Priority Date Filing Date
US06/193,200 Expired - Lifetime US4404137A (en) 1979-10-16 1980-10-02 Pyrazolo [3,4-b][1,5]benzodiazepine compounds
US06/426,580 Expired - Fee Related US4486591A (en) 1979-10-16 1982-09-29 4-Substituted-1-(3-[2-aminoanilino]-1-pyrazole-4-carbonyl)piperazine
US06/638,181 Expired - Fee Related US4542131A (en) 1979-10-16 1984-08-06 Substituted diazolo[b][1,5]benzodiazepines and their use as CNS agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US06/426,580 Expired - Fee Related US4486591A (en) 1979-10-16 1982-09-29 4-Substituted-1-(3-[2-aminoanilino]-1-pyrazole-4-carbonyl)piperazine
US06/638,181 Expired - Fee Related US4542131A (en) 1979-10-16 1984-08-06 Substituted diazolo[b][1,5]benzodiazepines and their use as CNS agents

Country Status (33)

Country Link
US (3) US4404137A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0027390B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5663987A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR850000471B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR228041A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT373889B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU538500B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE885729A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (2) BG34907A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1159056A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH646700A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS244409B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD153692A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3068706D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK437480A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8106905A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI67550C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2467851A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8327127D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR70720B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU182213B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE50358B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL61264A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1143047B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU82853A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX6233E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ195248A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH16288A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL135044B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT71913B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (2) RO85822B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU261580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA806342B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486591A (en) * 1979-10-16 1984-12-04 Lilly Industries Limited 4-Substituted-1-(3-[2-aminoanilino]-1-pyrazole-4-carbonyl)piperazine
US4492699A (en) * 1980-12-11 1985-01-08 Lilly Industries Limited Triazolobenzodiazepine derivatives
US4596799A (en) * 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
US4977150A (en) * 1988-08-11 1990-12-11 Lilly Industries Limited Benzodiazepine compounds and their use as pharmaceuticals
US20040224942A1 (en) * 2003-01-23 2004-11-11 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050192268A1 (en) * 2003-12-22 2005-09-01 Fredrik Ek Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW219896B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1988-07-07 1994-02-01 Duphar Int Res
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
JP5438482B2 (ja) * 2009-12-03 2014-03-12 Ｊｕｋｉ株式会社 ミシン、ミシンの縫製データ編集装置及びミシンの縫製データ編集プログラム

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450694A (en) * 1966-02-23 1969-06-17 Abbott Lab Substituted benzoxazepines and benzothiazepines
US3660380A (en) * 1968-08-20 1972-05-02 Boehringer Sohn Ingelheim 11-substituted 5 11-dihydro-6h-pyrido(2 3-b)(1 4)benzodiazepin-6-ones
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3761481A (en) * 1969-07-31 1973-09-25 Yoshitomi Pharmaceutical 11-(4-heterocyclic alkyl substituted-1-piperazinyl) dibenzooxazepines
US3951981A (en) * 1975-02-24 1976-04-20 American Cyanamid Company Substituted benzodiazepines and method of use
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
DE2707270A1 (de) * 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
EP0003016A1 (en) * 1977-10-31 1979-07-25 Sandoz Ag Pyrazino-benzoxazepine and -benzthiazepine derivatives, processes for their production and pharmaceutical compositions containing them
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4317823A (en) * 1979-08-03 1982-03-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazolobenzodiazepinones, their intermediates, their compositions and their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2707269A1 (de) * 1977-02-19 1978-08-24 Hoechst Ag Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
CH643263A5 (de) * 1979-05-11 1984-05-30 Sandoz Ag Benzodiazepine, ihre herstellung und verwendung.
US4404137A (en) * 1979-10-16 1983-09-13 Lilly Industries Limited Pyrazolo [3,4-b][1,5]benzodiazepine compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450694A (en) * 1966-02-23 1969-06-17 Abbott Lab Substituted benzoxazepines and benzothiazepines
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3660380A (en) * 1968-08-20 1972-05-02 Boehringer Sohn Ingelheim 11-substituted 5 11-dihydro-6h-pyrido(2 3-b)(1 4)benzodiazepin-6-ones
US3743734A (en) * 1968-08-20 1973-07-03 Boehringer Sohn Ingelheim Pharmaceutical compositions comprising an 11-aminoacetyl - 5,11 - dihydro-6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one
US3761481A (en) * 1969-07-31 1973-09-25 Yoshitomi Pharmaceutical 11-(4-heterocyclic alkyl substituted-1-piperazinyl) dibenzooxazepines
US4115574A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Benzodiazepine derivatives
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US3953430A (en) * 1975-02-24 1976-04-27 American Cyanamid Company Substituted benzodiazepin-10-ones and method of use
US3951981A (en) * 1975-02-24 1976-04-20 American Cyanamid Company Substituted benzodiazepines and method of use
DE2707270A1 (de) * 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
EP0003016A1 (en) * 1977-10-31 1979-07-25 Sandoz Ag Pyrazino-benzoxazepine and -benzthiazepine derivatives, processes for their production and pharmaceutical compositions containing them
US4317823A (en) * 1979-08-03 1982-03-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazolobenzodiazepinones, their intermediates, their compositions and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Plescia et al., Chem. Abstracts, vol. 92, Abstract No. 6514s, (1980). *
Rajappa et al., CA 85:177301e, (1976). *
Rajappa et al., Indian J. Chem., 1976, 14B, 394-396. *
Schneider et al., CA 80:14969m, (1974). *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486591A (en) * 1979-10-16 1984-12-04 Lilly Industries Limited 4-Substituted-1-(3-[2-aminoanilino]-1-pyrazole-4-carbonyl)piperazine
US4492699A (en) * 1980-12-11 1985-01-08 Lilly Industries Limited Triazolobenzodiazepine derivatives
US4596799A (en) * 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
US4977150A (en) * 1988-08-11 1990-12-11 Lilly Industries Limited Benzodiazepine compounds and their use as pharmaceuticals
US5051516A (en) * 1988-08-11 1991-09-24 Lilly Industries Limited Benzodiazepine compounds and their use as pharmaceuticals
US20090018119A1 (en) * 2003-01-23 2009-01-15 Acadia Pharmaceuticals, Inc. Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20040224942A1 (en) * 2003-01-23 2004-11-11 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2005063254A3 (en) * 2003-12-22 2005-09-15 Acadia Pharm Inc Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060194784A1 (en) * 2003-12-22 2006-08-31 Fredrik Ek Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060199798A1 (en) * 2003-12-22 2006-09-07 Fredrik Ek Amino bustituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20070197502A1 (en) * 2003-12-22 2007-08-23 Fredrik Ek AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS
US20050192268A1 (en) * 2003-12-22 2005-09-01 Fredrik Ek Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7491715B2 (en) 2003-12-22 2009-02-17 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7517871B2 (en) 2003-12-22 2009-04-14 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7550454B2 (en) 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7622461B2 (en) 2003-12-22 2009-11-24 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
ZA806342B (en) 1982-05-26
RO81351B (ro) 1983-02-28
CH646700A5 (fr) 1984-12-14
PL227306A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-09-18
IT8049899A0 (it) 1980-10-14
IE50358B1 (en) 1986-04-02
FR2467851A1 (fr) 1981-04-30
RO85822A (ro) 1984-11-25
KR850000472B1 (ko) 1985-04-08
YU261580A (en) 1983-12-31
AU6325280A (en) 1981-04-30
ATA510180A (de) 1983-07-15
IL61264A0 (en) 1980-12-31
HU182213B (en) 1983-12-28
ES495948A0 (es) 1981-09-16
EP0027390A1 (en) 1981-04-22
AR228101A1 (es) 1983-01-14
IT1143047B (it) 1986-10-22
KR830004300A (ko) 1983-07-09
ES8106905A1 (es) 1981-09-16
PL126824B1 (en) 1983-09-30
IL61264A (en) 1985-08-30
PH17759A (en) 1984-12-05
NZ195248A (en) 1983-11-18
LU82853A1 (fr) 1982-05-10
PT71913B (en) 1981-08-31
PH16288A (en) 1983-09-05
AU538500B2 (en) 1984-08-16
BG35042A3 (en) 1983-01-16
JPS5663987A (en) 1981-05-30
IE802135L (en) 1981-04-16
PL135044B1 (en) 1985-09-30
GB8327127D0 (en) 1983-11-09
FR2467851B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-04-05
CA1159056A (en) 1983-12-20
US4542131A (en) 1985-09-17
RO85822B (ro) 1984-11-30
PL231270A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-23
RO81351A (ro) 1983-02-15
FI803253L (fi) 1981-04-17
BE885729A (fr) 1981-04-15
KR850001463A (ko) 1985-03-18
CS244409B2 (en) 1986-07-17
AT373889B (de) 1984-02-27
FI67550B (fi) 1984-12-31
PT71913A (en) 1980-11-01
US4486591A (en) 1984-12-04
DK437480A (da) 1981-04-17
BG34907A3 (en) 1983-12-15
KR850000471B1 (ko) 1985-04-08
AR228041A1 (es) 1983-01-14
GR70720B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1983-01-18
DE3068706D1 (en) 1984-08-30
EP0027390B1 (en) 1984-07-25
MX6233E (es) 1985-01-14
FI67550C (fi) 1985-04-10
DD153692A5 (de) 1982-01-27

Similar Documents

Publication Publication Date Title
US4353827A (en) Diazepine derivatives
US4404137A (en) Pyrazolo [3,4-b][1,5]benzodiazepine compounds
US4115568A (en) Thieno[3,2-b]-[1,5]benzodiazepines
HU221017B1 (hu) Triciklusos benzazepin- és benzazocinszármazékok, továbbá az ezeket tartalmazó vasopressin antagonista hatású gyógyászati készítmények
FI68827B (fi) Analogifoerfarande foer framstaellning av nya terapeutiskt verkande 2-fenyl- eller -pyridyl-pyrazolo(4,3-c)kinolin-3(1 och5h)-oni-foereningar
US4172831A (en) Thieno-benzodiazepines
US4782057A (en) Benzo[h]cinnoline compound, a method of preparing said compound and a pharmaceutical composition
DK167681B1 (da) 3-benzyl-3h-1,2,3-triazolooe4,5-daapyrimidiner i fri form eller i saltform, fremgangsmaade til deres fremstilling, deres anvendelse som laegemiddel og til fremstilling af et farmaceutisk praeparat samt farmaceutisk praeparat og dettes fremstilling
US4492699A (en) Triazolobenzodiazepine derivatives
US5466706A (en) 9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their preparation and their therapeutic application
US5051516A (en) Benzodiazepine compounds and their use as pharmaceuticals
IE922342A1 (en) Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics
GB2106109A (en) Novel polycyclic polyazaheterocycles, processes for their manufacture and pharmaceutical preparations containing them
GB2063251A (en) Pyrazolobenzodiazepines
CA1164457A (en) Benzodiazepine compounds and their use as pharmaceuticals
US4510141A (en) Tricyclic polyazaheterocycles for treating depression or anxiety
Chakrabarti et al. Heteroarenobenzodiazepines. Part 7. Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo [3, 4-b] and [4, 3-b][1, 5] benzodiazepines as potential anxiolytics
CA2210631C (en) Tricyclic benzazepine vasopressin antagonists
FI113270B (fi) 3,3a-dihydrodibentso[b,f]isoksatsolo[2,3-d]oksatsepiini- ja -tiatsepiini-2-alkyyliamiinijohdannaisia, joilla on 5-HT2-reseptoriaffiniteetti, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeenä

Legal Events

Date Code Title Description
AS Assignment

Owner name: LILLY INDUSTRIES LIMITED LILLY HOUSE, HANOVER SQUA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CHAKRABARII, JIBAN K.;HOTTEN, TERRENCE M.;REEL/FRAME:004143/0603

Effective date: 19800923

Owner name: LILLY INDUSTRIES LIMITED,ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAKRABARII, JIBAN K.;HOTTEN, TERRENCE M.;REEL/FRAME:004143/0603

Effective date: 19800923

STCF Information on status: patent grant

Free format text: PATENTED CASE